Last week’s announcement of Cronos Group’s Q4 earnings temporarily lifted its stock price before continuing its decline.

Cronos’ Q4 sales stood at $1.6 million. YOY, this figure marks a growth of 274%, and 636% for the entire year.

 

Cronos Group, a recent IPO, is a Toronto-based marijuana company. Its CEO, Mike Gorenstein, addressing their earnings bump, expressed bullishness with regard to the company’s prospects:

“We are building Cronos Group with a focus on the long-term and 2017 set the foundation for the explosive growth we have already started realizing in 2018…We are extremely proud of all that our team has accomplished and look forward to a year of rapid increases in sales, commencing distribution in new markets, further developing disruptive intellectual property and launching new iconic brands.”

Points of Interest:

  • Cronos expects to increase production capacity and efficiency having completed improvements to three their production facilities.
  • They are launching a joint venture in Israel for the production and distribution of medical cannabis.
  • They have also begun distributing products through Pohl-Boskamp, a European pharmaceutical company.
  • The Pohl-Boskamp contract includes a 5-year agreement to distribute their product “Peach Naturals” to pharmacies in Germany.

The U.S. Justice Department’s stance on legal cannabis is a major driver of uncertainty and impediment to the cannabis industry’s potential. Despite the fundamental capacity exhibited by any companies operating in this space, this legal impediment constitutes an ever-present risk as it also constitutes a potentially bullish signal if or when lifted.

Technical Overview: Symmetrical Triangle and Uptrend

CRON-5-1-18-300x182 Cronos Group (CRON): A Potentially Undervalued Stock with Impressive Earnings

 

 

The risk of loss in the trading of stocks, options, futures, foreign exchanges, foreign equities, and bonds can be substantial and is not suitable for all investors. Trading on margin or the use of leverage is not suitable for all investors and losses exceeding your initial deposit is possible. Supporting documentation is available upon request. Trading futures, options on futures, and foreign exchanges involves substantial risk of loss and is not suitable for all investors. Carefully consider whether trading is suitable for you in light of your circumstances, knowledge, and financial resources and only risk capital should be used. Opinions, market data, and recommendations are subject to change at any time. The lower the margin used the higher the leverage and therefore increases your risk. Past performance is not necessarily indicative of future results.